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Abstract This article reports on the application of organi-
cally modified silica (ORMOSIL) nanoparticles as an effi-
cient in vitro gene delivery system in the recent years. Based
on that prime objective, the present study addresses the
possible ways to reduce cancers incidence at cellular level.
In this context, ORMOSIL nanoparticles had been synthe-
sized and incubated along with pCMV–Myc (3.8 kb) plas-
mid vector construct carrying p53gene, and transfected into
the breast cancer cell line MCF-7 cells. Western blot analy-
sis showed that the p53 protein was significantly expressed
in breast cancer cell upon transfection. The confocal and
electron microscopic studies further confirmed that the
nanoparticles were accumulated in the cytoplasm and the
nucleus of the cancer cells transfected with p53 gene. Inter-
esting agarose gel electrophoresis studies revealed that the
nanoparticles efficiently complex with pCMV–Myc vector.
The anti-cancer properties of p53 were demonstrated by
assessing the cell survival and growth rate which showed a
positive linear correlation in cancer cells. Whereas, the
growth rate was significantly reduced in ORMOSIL/p53/
pCMV–Myc transfected breast cancer cells compared to the
growth rate of non-transfected cells. The results of this
approach using ORMOSIL nanoparticles as a non-viral gene
delivery platform have a promising future for use as effec-
tive transfection agent for therapeutic manipulation of can-
cer cells and targeted cancer gene therapy in vivo.
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1 Introduction
Nanomedicine is an emerging new field created by the
combination of nanotechnology and medical sciences (Roy
et al. 2005). The application of nanotechnology to biomedical
research is expected to have a major impact in leading the
development of new types of diagnostic and therapeutic tools
(Prasad 2003, 2004). One focus in nanobiotechnology is the
development and use of non-viral vectors for safe and efficient
gene delivery (Davis 1997; Anderson 1992, 1998). With the
potential of gene transfer as a therapeutic tool, the application of
nanotechnology in the development of non-viral transfection
agents for gene therapy is need of the hour (Bharli et al. 2005).
The chances of using viral vectors as gene carriers is limited
because of the risk factors such as pathogenicity, immunoge-
nicity etc., and there is a need to supply a sufficient amount of
DNA to the surface of the cells for effective gene transfer (Luo
and Saltzman 2000). In spite of these limitations, the research
focus has shifted towards the development of nanoparticle
dependent gene delivery system. The other major advantages
of nanoparticle vectors were the absence of limitations on the
size and number of gene inserts. Ultrafine silica nanoparticles,
with surfaces functionalized by cationic-amino groups, have
been shown to not only bind and protect plasmid DNA from
enzymatic degradation but also to transfect efficiently cultured
cells and express encoded proteins (Allister et al. 2002; Kneuer
et al. 2000a, b). Silica nanoparticles modified with aminosi-
lanes [either N-(2 aminoethyl)-3 aminopropyltrimethoxysilane
or N-(6-aminohexyl)-3 aminopropyltrimethoxysilane] are able
to condense and deliver DNA, very much like cationic poly-
mers (He et al. 2003; Kneuer et al. 2000a, b), without the
addition of other cationic transfection reagents (Kneuer et al.
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2000a, b). Other cationic silica nanoparticles with surfaces
modified by aminohexyl-aminopropyltrimethoxysilane
(AHAPS) are also reported to be successful transfection
reagents (Ravi Kumar et al. 2004). Organically modified silica
(ORMOSIL) nanoparticles have a potential to overcome many
limitations of their “unmodified” silica counterparts. The pres-
ence of both hydrophobic and hydrophilic groups on the pre-
cursor alkoxyorganosilane helps them to self-assemble both as
normal micelles and reverse micelles under appropriate con-
ditions. The resulting micelles (and reverse micelles) cores can
be loaded with bio-molecules such as drugs, proteins, etc.
(Bharali et al. 2003). Such a system has number of advantages:
(1) they can be loaded with either hydrophilic or hydrophobic
drugs/dyes; (2) they can be precipitated in oil-in-water micro-
emulsions in which corrosive solvents such as cyclohexane and
complex purification steps such as solvent evaporation, ul-
tracentrifugation, etc. can be avoided; (3) their organic groups
can be modified further for attachment of targeting molecules;
and (4) they can be possibly biodegraded through the biochem-
ical decomposition of the Si–C bond (Bacskai et al. 2003). The
presence of the organic group also imparts some degree of
flexibility to the otherwise rigid silica matrix, which is expected
to enhance the stability of such particles in an aqueous system
against precipitation. In the present work, the hybrid amino-
functionalized ORMOSIL nanoparticles have been synthesized
by a synchronous hydrolysis of vinyltriethoxysilane (VTES)
and 3-aminopropyltriethoxysilane (APTES). By varying the
concentrations of Aerosol-OT and VTES, monodispersed
nanoparticles of the mean diameter of the ORMOSILNs were
under 60 nm which are highly stable in aqueous conditions
(Das et al. 2002). Furthermore, the nanoparticles have been
characterized by zeta potential measurement, XRD, and FTIR.
The amino-functionalized nanoparticles were able to electro-
statically condense DNA (both plasmid and genomic) and
protect it from enzymatic degradation. Using confocal micros-
copy, it was found that the fluorescently labeled nanoparticles
extensively accumulated in the cytoplasm and the nucleus of
cancer cell lines used for the study (Jain et al. 1998). It was
found that the nanoparticles release the genetic material inside
the cytoplasm, which diffuses to the nucleus, a prerequisite for
successful gene therapy. The present study clearly demonstrates
the transfection efficiency of ORMOSIL nanoparticles as non-
viral vectors, which are shown by the expression of p53 genes
in the breast carcinoma cell lines.
2 Experimental
2.1 Materials
ORMOSIL precursors are surfactant (Aerosol-OT 98 %) and
co-surfactant (n-butanol 99.8 %), vinyltriethoxysilane (VTES
97 %), 3-aminopropyltriethoxysilane (APTES 99 %), and
dimethyl sulfoxide (DMSO 99.5 %). The human cancer cell
lines such as MCF-7 were generously donated by King Insti-
tute of Preventive Medicine Chennai (Dr. P. Gunasekaran’s
laboratory). DMEM was purchased from Sigma, USA. The
cells were seeded into 25-mm culture flasks and incubated at
37°C, in 5 % CO2. pCMV plasmid construct carrying anti-
cancer protein p53 was purchased from Clontech. GFP was
purchased from Invitrogen (Bangalore, India).
2.2 Preparation of ORMOSIL nanoparticles
The nanoparticles were synthesized in the non-polar core of
Aerosol-OT/DMSO/water micelles as reported by Roy et al.
and is briefly outlined as follows: Typically, the micelles were
prepared by dissolving 0.44 g Aerosol-OT and 800 μl n-
butanol in 20 ml of double-distilled water by vigorous mag-
netic stirring. One hundred microliters of DMSO was added.
After that, 200 μl of neat VTES was added to the micelles
system and the resulting solution was stirred for ~30 min.
Furthermore, the ORMOSIL nanoparticles were precipitated
by adding aqueous ammonia solution or APTES and stirring
for ~20 h at room temperature using a magnetic stirrer. For-
mation of the nanoparticles is indicated by a white blue color.
Surfactant Aerosol-OT and co-surfactant n-butanol were re-
moved by dialyzing the aqueous solution against distilled
water in a 12- to 14-kDa cut-off cellulose membrane for
50 h. The dialyzed solution was filtered through a 0.2-μm
cut-off membrane filter and used straightway for further
experimentation.
2.3 Characterization of ORMOSIL nanoparticles
Transmission electron microscopy was used to determine
the morphology and the size of the aqueous dispersion of
nanoparticles with a JEOL JEM 2020 electron microscope
operating at an accelerating voltage of 200 kV. X-ray dif-
fraction using Cukα radiation (PAN analytical X’pert Pro
MPD diffractometer) was used to determine the amorphous
structure of ORMOSIL nanoparticles. Powder X-ray analy-
sis was carried out using a Philips Model PW 1050/37
diffractometer, operating at 40 kV and 30 mA, with a step
size of 0.02° (2θ). Dried and powdered samples of colloids
with the stabilizer before and after heat treatment were used
for the measurements. The surface groups of the nanopar-
ticles were qualitatively confirmed using FTIR spectrosco-
py. FTIR spectra were recorded on a Perkin-Elmer spectrum
2000 FTIR spectrophotometer. The pellets of the lyophilized
powder were made with dried KBr. The size distribution of
ORMOSILNs alone and their complexes with various
amounts of DNA was measured by quasi-elastic light scat-
tering (QLS) using Nicomp-370 (Nicomp Particles Sizing
System, Santa Barbara, USA). For particle size analysis of
the complexes, the complexes were diluted with phosphate-
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buffered saline (PBS) just prior to size measurement. The
change in the particle diameter of complexes was measured
for 3 min using Gaussian analysis. The zeta potential of
complexes was analyzed using an electrophoretic light scat-
tering spectrophotometer (ELS-8000, OTSUKA Electronics
Co. Ltd., Japan) at room temperature to monitor the electro-
phoretic mobility of transfected complexes.
2.4 Nano-DNA complex preparation
We examined the complex formation of plasmid DNA with
nanoparticles by agarose gel electrophoresis. DNA loading of
ORMOSIL nanoparticles was accomplished by incubation
with pCMV/p53 for 30 min at room temperature. The result-
ing ORMOSIL/pCMV/p53 nanoparticles were suspended in
phosphate-buffered saline (PBS; 140 μg/ml DNA). The com-
plex formation were run on 1 % agarose at 100 V for 1.5 h,
subsequently stained with ethidium bromide, and documented
by using a gel documentation system. Genei Ultraviolet
Benchtop transilluminator was used in conjugation with an
Olympus Digital Camedia C-4000 Zoom color camera with a
UV filter and lens. The documentation was completed by
using the DOC-IT system software.
2.5 In vitro transfection
MCF-7 (human breast carcinoma) cells were seeded in 24-
well tissue culture plates at a density of 2×105 cells/well. The
cells were allowed to adhere overnight as a monolayer and to
achieve 70–80 % confluence. Transfection complexes were
prepared by mixing the plasmid DNA (p53–pCMV) with
ORMOSILNs and were incubated for 15 min at room tem-
perature before in vitro studies. Prior to transfection, 800 μl of
serum-free DMEM was added to each well; 100 μl of trans-
fection complexes mixed with 2 μg of the plasmid DNA and
various amounts (6–48 μg) of ORMOSILNs were then added
to each of the wells. After 5 h of incubation at 37°C under 5 %
CO2, cells were rinsed and cultured for 24 h in 1ml ofmedium
containing 10 % (FBS).
2.6 Western blot analysis
The levels of p53 protein expression in transfected cells with
the plasmid DNA/ORMOSILNs complexes were deter-
mined by Western blot analysis. The transfected cells were
harvested and lysed in lysis buffer (150 mM NaCl; 20 mM
Tris base, pH 7.5; 1 mM PMSF; 1 mM Na3VO4; 25 mM
NaF; 1 % aprotinin; 10 μg/ml leuprotinin; 1 % Triton X-
100; 1 % NP-40) on ice for 30 min. After samples were
centrifuged at 12,000 rpm for 10 min, the protein concen-
trations of supernatants were determined by Bio-Rad DC
(detergent-compatible) microprotein assay using bovine se-
rum albumin (BSA) as a protein standard. Then 15-μg
aliquots of proteins were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS–PAGE)
and transferred to nitrocellulose filters. The nitrocellu-
lose membrane was incubated for 1 h in a blocking
buffer (5 % non-fat milk in PBS) followed by incuba-
tion with the mouse anti-human p53 antibody (Pab240,
Santa Cruz, CA, USA).
2.7 Cell viability
The effects of the plasmid DNA/ORMOSILNs complexes
on growth inhibition were determined using a cell growth
assay. The MCF-7 cells were seeded in six-well plates at a
density of 1×104 cells/well. After 24 h, the cells were trans-
fected with the plasmid DNA alone, DNA/ORMOSILNs, or
DNA/Lipofectin® complexes, respectively. After transfec-
tion, the amounts of viable adherent cells were determined
by trypan blue exclusion assay performed every other day.
Untreated cells were used as a control. Growth assays were
performed in triplicate.
2.8 Statistical analysis
Statistical analysis of data was performed using Student’s
t test and analysis of variance (ANOVA). A p value less
than 0.05 were considered significant.
3 Results and discussion
3.1 Physicochemical characteristics of ORMOSILNs
Figure 1 shows transmission electron microscopy images of
ORMOSIL nanoparticles. Note that the particles are spher-
ical in shape and highly monodispersed. For the preparation
of cationic ORMOSILNs, VTES was selected as a silica
component that would constitute the core of the ORMO-
SILNs. Aerosol-OT, DMSO, and APTES were used as
cationic ORMOSIL, helper VTES, and surfactant, respec-
tively. The mean diameter of the ORMOSILNs was under
60 nm, which is generally known to be an effective size for
high transfection efficiency. The zeta potentials of ORMO-
SILNs and ORMOSILNs/DNA were approximately 8 and
13 mV, respectively. To investigate whether the changes in
the packing material or storage conditions may further im-
prove the stability of freeze-dried ORMOSILNs, ORMO-
SILNs were freeze-dried using sucrose as a cryoprotectant,
and the particle diameter and transfection efficiency were
subsequently determined. The particle diameters of ORMO-
SILNs and ORMOSILNs/DNA were slightly increased but
both of them were under 60 nm. We also compared the
transfection efficiencies of the ORMOSILNs before freeze
drying (Table 1).
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3.2 X-ray diffraction analysis
The vinyltriethoxysilane (VTES) 3-aminopropyltriethoxysilane
(APTES) capped ORMOSIL nanoparticles (Fig. 2) were inves-
tigated by X-ray diffraction technique. In the selected constitu-
ent concentration, spherical ORMOSIL nanoparticle can be
obtained as colloidal ORMOSIL nanoparticles that are based
on the hydrolysis and polycondensation of VTES in the aque-
ous core of the reverse micelles droplets. The reaction contin-
ued until the solution is supersaturated. To investigate the
possibility of tailoring the particle size distribution, a kinetic
study of the particle size evolution as a function of reaction time
was carried out. The ORMOSILNs were amorphous according
to XRD with peaks on 2θ0220 conforming to the JCPDS
parameters 27.1402. This demonstrated that a high percentage
of these particles are amorphous besides a few of them that
were crystalline in nature (Bolton and Kearns 1978; Vacassy et
al. 2000).
3.3 FTIR analysis
The nanoparticle surface design involves an optimum balance
of the use of inert and active surface functional groups to
achieve minimal nanoparticle aggregation and reduce nano-
particle non-specific binding. Silica nanoparticles were pre-
pared in a water-in-oil microemulsion and subsequently
surface-modified via co-hydrolysis with tetraethylorthosilicate
(TEOS) and organosilane reagents. Nanoparticles with different
functional groups, including amine and amine/phosphonate,
were produced in the present investigation. The FT-IR spectrum
(Fig. 3) of synthesized hybrid amino-functionalized ORMOSIL
nanoparticles by a synchronous hydrolysis of VTES and 3-
aminopropyltriethoxysilane (APTES) sample shows peaks
around 1,730 and 3,516 cm−1 corresponding to the carboxyl
and hydroxyl groups (Shan et al. 2000). The IR spectrum shows
the peaks for NH2 group as well as silica. The amino-
functionalized nanoparticles are able to electrostatically
condense DNA (both gene of interest and genomic) and
protect it from enzymatic degradation. Hence, silica was
functionalized with amino group in the present investi-
gation. Furthermore, in the given IR spectrum the amino
group peaks were noticed between 3,000 and 3,600
(stretched vibration) and also between 1,550 and 1,640
(bending vibration). Interestingly, the peak for silica is
observed between 1,000 and 1,250.
Respectively, the FT-IR peaks belong to the Si–O stretch-
ing vibration of Si–OH bond. A strong peak near 1,046,
773, and 467 cm−1 has been assigned to Si–O Si stretching
bond which implies the condensation of silicon alkoxide in
monomer vinyltriethoxysilane (VTES). The presence of the
vinyl group in VTES can usually be recognized by the
presence of a minimum intensity of broad band at
3,516 cm−1 due to the unsaturated 0C–H stretching vibra-
tion. In plane bending vibration of the group 0C−H
−H in the
presence of VTES peak at 1,406 cm−1 and C0C stretching
vibration give shift to an absorption at 1,646 cm−1 (Vogel
1989). The two bands at 2,959 and 2,870 cm−1 were
assigned to the asymmetric and symmetric stretching vibra-
tion modes of the CH3 and CH2 groups in presence of VTES
and APTES (Sharma et al. 2004). Rocking vibration of the
Fig. 1 Transmission electron microscopy images of highly monodis-
persed ORMOSIL nanoparticles
Table 1 The mean diameters and zeta potentials of ORMOSILNs
components (n03)
Nanoparticles Size (nm) Zeta potential (mV) Transfection
efficiency




Fig. 2 Representative XRD diffraction pattern of ORMOSIL nano-
particles, respectively
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CH3 groups at 1,165 cm
−1 was present in VTES, and Si–C
bands at 773 and 1,218 cm−1 peaks were seen (Table 2).
3.4 Examination of the complex formation of plasmid DNA
with nanoparticles
For non-viral gene delivery, we have developed and tested the
formation of nanoparticles which consist of a stable aqueous
dispersion of ultrafine ORMOSIL nanoparticles. ORMOSIL-
based nanoparticles can be synthesized with varying surface
change and are stable (non-aggregating) in aqueous environ-
ments. The genetic payload (negative charged DNA) is bound
to the cationic group present on the surface of the nanoparticles.
The non-aggregating potential, coupled with the designed abil-
ity to bind and protect DNA, provides a second platform from
which a non-viral gene transfer vector will be produced and
tested. The nanoparticles for DNA delivery are functionalized
with amino group, which made it possible to electrostatically
attach DNA molecules on the surface as shown schematically
in Fig. 4. Nanoparticles were found to have high efficiency for
the formation of ORMOSIL DNA complex. Figure 5 repre-
sents the results of agarose gel electrophoresis of plasmidDNA,
free and complexes with ORMOSIL nanoparticles. It can be
seen that with increasing amounts of amino groups (positive
charge) on the nanoparticles, the mobility of the DNA com-
plexes toward 50 μl, 30 μl, and 10 μl retards the positive
terminal (lanes 3–5). This result suggests that the plasmid is
nomore able tomove freely because the resulting nanoparticle–
DNA complex has restricted the mobility in the gel. After
treatment with DNase 1, the free plasmid is completely digested
(Fig. 5, lane 6). The reason for this protection against enzymatic
digestion is not yet fully understood. It was suggested recently
that this behavior can be due to (1) repulsion of Mg2+ ions
(which are necessary for the enzymatic reaction) by the amino
groups, (2) a hindered access of the enzymes to the DNA that is
immobilized on the nanoparticle surface, or (3) both (He et al.
2003). Note that the plasmid treated with the non-amino termi-
nated particle (ORMOSIL) is also partially protected (Fig. 5,
lane 2) because it has bands corresponding to both its non-
enzymatically treated counterpart (Fig. 5, lane 3) and also some
DNA fragments appearing at the bottom of the band. Therefore,
these nanoparticles can also be considered as some kind of
inhibitors toward the enzymatic action of DNase 1 on plasmid
DNA. Alternatively, it is also possible that the interaction
between the genetic material and the nanoparticle will not be
entirely of electrostatic nature.
3.5 Western blot analysis for p53 expression
In order to evaluate the uptake of p53 genes into MCF-
7 by nanoparticles, the transfected MCF-7, after 3 days
of culturing, were detected via Western blotting with
protein-specific antibodies (Fig. 6). As shown in the
figure, protein levels of the p53 of MCF-7 were signif-
icantly increased by the ORMOSIL nanoparticles. In
contrast, the protein level of the p53 genes in MCF-7
Fig. 3 FTIR spectra of neat
VTES and APTES ORMOSIL
nanoparticles
Table 2 IR peak (cm−1) of VTES and APTES, ORMOSIL nanopar-
ticles present in chemical compounds
S. no Peaks values (cm−1) Name of the compound
and functional groups
1. 1,730, 3,516 (Si–O), (Si–OH)
2. 1,046, 773, 467 (Si–O–Si)
3. 31,406, 1,646 (C0C)
4. 2,959, 2,870 (CH3), (CH2)
5. 773, 1,218 (Si–C)
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using ORMOSIL carriers was found to be highly in-
creased. However, the expression of p53 genes in MCF-
7 was slightly detected in the Lipofectin® via Western
blot analysis. This means that the ORMOSIL nanopar-
ticles predominantly expressed the p53 genes in MCF-7
as compared to the other gene carriers. Via the expres-
sion of p53 genes in MCF-7, ORMOSIL nanoparticles
appear to be superior gene delivery vehicles.
3.6 In vitro growth assay
Using in vitro growth assay, the effect of the transfection of
p53–pCMV/ORMOSILNs on the rate of MCF-7 cell growth
was determined by measuring the doubling time compared to
that of uninfected control cells. On day 0, the cell lines were
passed into monolayer cultures in 24-well flat-bottomed micro-
plates. The following day, the cells were transfected with
plasmid DNA alone, DNA/ORMOSILNs, or DNA/Lipofec-
tin®. The growth rate of p53–pCMV/ORMOSILNs-transfected
Fig. 4 Schematic of
ORMOSIL nanoparticle
compositions
Fig. 5 Image of agarose gel electrophoresis of plasmid DNA, free and
complexed with ORMOSIL nanoparticles. Lane 1 λ-DNA HindIII
digest, 2 pCMV, 3 ORMSIL+pCMV (50 μl), 4 ORMSIL+pCMV
(30 μl), 5 ORMOSIL+pCMV (10 μl), 6 pCMV+DNase 1
Fig. 6 Western blots analysis of p53 protein in p53/pCMV-transfected
MCF-7 cells
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cells was significantly inhibited compared with control cells or
cells transfected with p53 DNA alone (Fig. 7). These results
indicate that ORMSILNs-mediated p53 DNA delivery
inhibited the growth of MCF-7 cells. Transfection of MCF-7
cells with p53 DNA alone had a slight effect on cell growth
compared to the uninfected cells. Thus, the inhibitory p53–
pCMV/ORMOSILNs transfection in MCF-7 cells is likely due
to the expression of p53 protein.
Efficient inhibition of cell growth by p53–pCMV/
ORMOSILNs complexes indicates that these complexes
would be efficient not only in increasing the expression of
p53 proteins but also in inhibiting the growth of breast
cancer cells.
3.7 Gene transfer efficiency of ORMOSIL nanoparticles
The efficiency of ORMOSIL nanoparticles mediated transfor-
mation was analyzed using a transmission electron micro-
scope (TEM) at cellular level. Figure 8 shows that the
ORMOSIL nanoparticles are highly dispersed in the cyto-
plasm of transformed breast cancer cell line MCF-7 cells.
There was no cellular distortion present on TEM images of
breast carcinoma cells exposed to ORMOSIL nanoparticles
alone. All organelles are intact and the cells imaged are
unchanged except for the presence of ORMOSIL nanopar-
ticles. Normally for breast carcinoma cells, the nuclear cyto-
plasmic ratio is very low. Lower concentration of nuclear
cytoplasm ratio in transformed breast carcinoma cells was
also confirmed by TEM image. Furthermore, at ×100,000
magnification, ORMOSIL nanoparticles of various sizes that
are dispersed in cytoplasm are clearly visible. A previous
study reported that hydrophobic dye-doped ORMOSIL nano-
particles are actively taken up by tumor cells in vitro, as seen
Fig. 7 The in vitro growth inhibition of the MCF-7 cells after trans-
fection with DNA/ORMOSILNs complexes. The number of adherent
cells was determined at each time point. Each point indicates the mean
±SD of values obtained from the assay of cells from six replicate
microtiter plate wells. *p<0.05, compared with the in vitro growth
inhibition of the control
Fig. 8 Transmission electron
microscopic analysis of
ORMOSIL nanoparticles
transfection at cellular level. a
The ORMOSILNs are mainly
distributed in the cytoplasm of
MCF-7. The arrow indicates
the ORMOSILNs. b Non-
transfected cells (control). c
ORMOSILNs distribute in the
cytoplasm at ×100,000 magni-
fication. The arrow indicates
the ORMOSILNs in different
sizes. d Non-transfected cells
at ×100,000 magnification
(control)
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by fluorescence staining of the cytoplasm (Roy et al. 2003).
This cytoplasmic staining is observed for several types of tumor
cells that we have investigated, an example of which is shown
for MCF-7 cells in (Fig. 9). Although the mechanism of this
cellular uptake is not yet fully understood, the net positive
charge on the nanoparticles has been thought to play a crucial
role. A similar observation was found in a recent study that has
demonstrated high non-specific uptake of anionic magnetic
nanoparticles by cells in vitro (Wilhem et al. 2003). In gene
delivery, the genetic material, as soon as it is released inside the
cytoplasm of a cell, shouldmigrate to the nucleus (Davis 1997).
Again, optical imaging can play a significant role in studying
this nuclear migration of DNA. In our experiment, we irrevers-
ibly labeled DNA with the fluorescent dye GFP and DAPI
complexed with unlabeled ORMOSIL nanoparticles as de-
scribed. The post-release nuclear trafficking of DNA is dem-
onstrated in the confocal image ofMCF-7 cells in Fig. 9a. After
comparison of this image with the image of MCF-7 cells
stained with DAPI encapsulated nanoparticles (Fig. 9b), it can
be seen that in addition to the cytoplasmic staining, there is
considerable staining inside the nucleus. Optimal transfection
conditions were evaluated by varying the amounts of plasmid
DNA at different ORMOSIL/DNA ratios, incubation times,
and media in order to form the complexes. Figure 9c and d
shows finally the expression of nano-DNA complex as con-
firmed by DAPI fluorescent stain with the help of fluorescent
microscopy. The 4-h incubation of the nano-DNA complex
with breast cancer cell line MCF-7 showed that the nano-
DNA complex was taken up completely by the cell as com-
pared to 2 h of incubation. We observed that pCMV–p53 was
transfected successfully by using the ORMOSIL nanoparticles
as the non-viral delivery vector.
4 Conclusions
The present study shows that the nanomedicine approach
using ORMOSIL nanoparticles provides a promising direc-
tion for non-viral gene delivery. In the present context, the
use of DAPI, together with fluorescence imaging, estab-
lished DNA delivery to the cell nucleus, whereas the use
of pCMV/p53 western blot provided evidence for the func-
tionality of delivered DNA. Our findings provide additional
information regarding the delivery of p53 gene into a se-
lected breast cancer cell line which is perfectly expressed in
the cells. Thus, the ORMOSILNs are recommended. In
particular, the effective indicated that the ORMOSILNs-
mediated delivery of p53 gene might show potential for
clinical use in non-viral vector mediated breast cancer
therapies.
Acknowledgments We thank R. Paulmurugan, Department of
Radiology–Diagnostic Radiology, Stanford University, for useful
discussion and All India Institute of Medical Sciences New Delhi
for their excellent technical support for taking confocal, electron,
and fluorescent microscopy results. Other technical support was
provided by Centre for Life Science DRDO Bharathiar University
Fig. 9 Confocal and
fluorescence images of cancer
cells treated with ORMOSILNs
previously incubated with DNA
labeled with ethidium
monoazide (EMA). a Confocal
bioimaging of cancer cells
demonstrating expression of
green fluorescent protein fol-
lowing in vitro administration.
b Fluorescent image of nano-
DNA complex stained with 4′-
6-diamidino-2-phenylindole
(DAPI). c 2-h incubation of
nano-DNA complex with cells
shows that the nanoparticles are
present outside the cells. d
Transformed into cells after
4-h incubation
62 C. Rejeeth et al.
Coimbatore. This work is financially supported by the DST-
Nanomission Division, Ministry of Science and Technology, Gov-
ernment of India (Ref. DST/SR/NM/NS-60/2010).
Competing interests The authors declare that they have no compet-
ing interests
References
Allister MK, Sazani P, Adam M, Cho MJ, Rubinstein M, Samulski RJ,
Desimone JM (2002) Polymeric nanogels produced via inverse
microemulsion polymerization as potential gene and antisense
delivery agents. J Am Chem Soc 124:15198–15207
Anderson WF (1992) Human gene therapy. Science 256:808–813
Anderson WF (1998) Human gene therapy. Nature 392:25–30
Bacskai BJ, Skoch J, Hickey GA, Allen R, Hyman BT (2003)
Fluorescence resonance energy transfer determinations using
multiphoton fluorescence lifetime imaging microscopy to
characterize amyloid-beta plaques. J Biomed Opt 8:368–375
Bharali DJ, Sahoo SK, Mozumdar S, Maitra A (2003) Cross-linked
polyvinylpyrrolidone nanoparticles: a potential carrier for hydrophilic
drugs. J Colloid Interface Sci 15:415–423
Bharli DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Bergey KN,
Prasad N, Stachowiak MK (2005) Organically modified silica
nanoparticles: a nonviral vector for in vivo gene delivery and expres-
sion in the brain. Proc Natl Acad Sci USA 102(2005):11539–11544
Bolton PH, Kearns DR (1978) Spectroscopic properties of ethidium
monoazide: a fluorescent photoaffinity label for nucleic acids.
Nucleic Acids Res 5:4891–4903
Das S, Jain TK, Maitra A (2002) Inorganic–organic hybrid nanopar-
ticles from n-octyl triethoxy silane. J Colloid Interface Sci
252:82–88
Davis SS (1997) Biomedical applications of nanotechnology—implications
for drug targeting and gene therapy. Trends Biotechnol 15:217–224
He XX, Wang K, Tan W, Liu B, Lin X, He C, Li D, Huang S, Li J
(2003) Bioconjugated nanoparticles for DNA protection from
cleavage. J Am Chem Soc 125:7168–7169
Jain TK, Roy I, De TK, Maitra AN (1998) Nanometer silica particles
encapsulating active compounds: a novel ceramic drug carrier. J
Am Chem Soc 120:11092–11095
Kneuer C, Sameti M, Bakowsky U, Sciestel T, Schirra H (2000a) A
nonviral DNA delivery system based on surface modified silica
nanoparticles can efficiently transfect cells in vivo. Bioconjug
Chem 11:926–932
Kneuer C, Sameti M, Haltner EG, Schiestel T, Schirra H, Schmidt H,
Lehr CM (2000b) Silica nanoparticles modified with aminosilanes
as carriers for plasmid DNA. Int J Pharm 196:257–261
Luo D, Saltzman WM (2000) Enhancement of transfection by physical
concentration of DNA at the cell surface. Nat Biotechnol 18:893–895
Prasad PN (2003) Introduction to biophotonics. Wiley, New York
Prasad PN (2004) Nanophotonics. Wiley, New York
Ravi Kumar MN, Sameti M, Mohapatra SS, Kong X, Lockey RF,
Bakowsky U, Lindenblatt G, Schmidt H, Lehr CM (2004) Cat-
ionic silica nanoparticles as gene carriers: synthesis, characteriza-
tion and transfection efficiency in vitro and in vivo. J Nanosci
Nanotechnol 4:876–881
Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan
J, Dougherty TJ, Prasad PN (2003) Ceramic-based nanoparticles
entrapping water-insoluble photosensitizing anticancer drugs:
a novel drug-carrier system for photodynamic therapy. J Am
Chem Soc 125:7860–7865
Roy I, Ohulchanskyy TY, Mistretta RA, Bharali DJ, Kaur N, Pudavar H,
Prasad PN (2005) Optical tracking of organically modified silica
nanoparticles as DNA carriers: a nonviral, nanomedicine approach
for gene delivery. Proc Natl Acad Sci U S A 102:279–284
Shan Y, Gao L, Zheng S (2000) A facile approach to load CdSe
nanocrystallites into mesoporous SBA-15. Mater Chem Phys
88:192–196
Sharma RK, Das S, Maitra A (2004) Surface modified ormosil
nanoparticles. J Colloid Interface Sci 277:342–346
Vacassy R, Flatt RJ, Hofmann H, Choi KS, Singh RK (2000) Synthesis
of microporous silica spheres. J Colloid Interface Sci 2:302–315
Vogel AL (1989) Textbook of practical organic chemistry. ELBS, UK
Wilhem C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F
(2003) Intracellular uptake of anionic superparamagnetic
nanoparticles as a function of their surface coating. Bioma-
terials 24:1001–1011
Development of in vitro gene delivery system using ORMOSIL 63
